{"id":909368,"date":"2025-11-13T03:03:59","date_gmt":"2025-11-13T08:03:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clarivate-companies-to-watch-report-spotlights-seven-womens-health-startups-shaping-the-future-of-care\/"},"modified":"2025-11-13T03:03:59","modified_gmt":"2025-11-13T08:03:59","slug":"clarivate-companies-to-watch-report-spotlights-seven-womens-health-startups-shaping-the-future-of-care","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clarivate-companies-to-watch-report-spotlights-seven-womens-health-startups-shaping-the-future-of-care\/","title":{"rendered":"Clarivate Companies to Watch Report Spotlights Seven Women’s Health Startups Shaping the Future of Care"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health<\/i>\n <\/p>\n

\n
\n LONDON<\/span>
\n <\/span>, Nov. 13, 2025<\/span><\/span> \/PRNewswire\/ — Clarivate Plc<\/a> (NYSE: CLVT), a leading global provider of transformative intelligence, today released its latest Companies to Watch report, Rediscovering Women’s Health<\/a>, highlighting seven companies driving innovation across reproductive care, chronic disease and mental health. Drawing on proprietary data, expert analysis and insights into therapeutic impact, financing activity and R&D momentum, the report showcases why these companies are recognized as high-impact innovators.<\/p>\n

\n

\n
\n \"Clarivate
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Despite representing half the global population, women remain underrepresented in clinical research and healthcare investment, with women’s health accounting for just 15% of venture capital and 5% of global healthcare R&D funding. Rediscovering Women’s Health highlights organizations addressing these gaps through inclusive research, novel therapies and a deeper understanding of female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS) and endometriosis, factors that influence broader outcomes like cardiovascular disease and dementia. The report also highlights growing momentum in women’s health R&D.<\/p>\n

\n
\n Anne Lecocq<\/span>, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said:<\/b> “Women’s health is no longer being defined solely by reproductive care; it’s being reframed through a broader lens that recognizes how biological and social factors shape outcomes across every therapeutic area. This shift marks a pivotal moment for the industry, as data-driven innovation and inclusive research begin to translate into more equitable care and better health outcomes for women worldwide. By spotlighting organizations driving this change, the Companies to Watch report underscores how scientific insight and investment can work together to close persistent gaps and advance women’s health globally.”<\/p>\n

\n Agn\u00e8s Arbat, MD, Co-Founder and CEO, Oxolife, said:<\/b>\u00a0“The next era of women’s health innovation will be defined by science that recognizes women’s unique biology as the foundation for discovery. Across the industry, we’re seeing a long-overdue shift toward inclusive research and smarter, more targeted therapies that can truly transform outcomes for women.”<\/p>\n

These companies are pioneering solutions that challenge outdated paradigms and promote equitable care. Clarivate analysts reviewed deal valuations, clinical trials, patents and market approvals to identify seven Companies to Watch in the space:<\/p>\n